retatrutide ly3437943 glp-1 gip glucagon receptor agonist Retatrutide, a GIP, and agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA GLP-3 (R) - Triple GIP

Start with a quick questionnaire to explore how we can support your menopause journey and help you manage your health more effectively

Signal Transduct Target Ther 8 , 372 (2023)

High level of homocysteine is associated with an increased risk of heart disease

Klinic offers assistance in securing prescriptions and managing weight loss treatment plans, ensuring coverage through weight loss medication insurance

Implications for obesity care & access The approval adds to the rapidly expanding landscape of GLP-1-based therapies for obesity, where injectables have dominated clinical practice and significantly shifted treatment paradigms

Blundell C, Tess ER, Schanzer AS, Coutifaris C, Su EJ, Parry S, Huh D (2016) A microphysiological model of the human placental barrier